Lucie J.
- Country
- Czechia
- Department
- NA
Research Overview
- Phase 3 Extension Study of Long-Term Safety and Efficacy of Remibrutinib in Adults With Moderate to Severe Hidradenitis Suppurativa
- Phase 3 Evaluation of Remibrutinib Efficacy and Safety in Adults with Moderate to Severe Hidradenitis Suppurativa
- A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
Data & Insights
Has run more than one trial at 66 of 255 partner sites.
Specializations
Hidradenitis Suppurativa
Lucie Jaresova’s clinical research activity is centered on hidradenitis suppurativa, with attention to inflammatory skin disease management in adult and adolescent patients. Her work is aligned with therapeutic evaluation in moderate to severe disease, where symptom control and skin lesion improvement are key clinical priorities.
- Inflammatory dermatology
- Chronic skin disease
- Disease severity assessment
Her research setting in Prague at DermaMedEst s.r.o. places her within a focused dermatology environment dedicated to treatment-oriented investigation in this condition.
Targeted Immunomodulatory Therapy
Her trial involvement includes evaluation of remibrutinib as a therapeutic option for hidradenitis suppurativa, reflecting interest in immune-mediated skin inflammation and emerging treatment strategies for difficult-to-manage dermatologic disease.
- BTK inhibition
- Immune-mediated inflammation
- Novel dermatologic therapy
This area of work connects dermatology with targeted immunotherapy, supporting clinical evaluation of treatments designed to address persistent inflammatory activity.
Clinical Outcome Evaluation
Her research landscape includes assessment of clinically meaningful endpoints in hidradenitis suppurativa, with emphasis on treatment response and improvement in disease burden. The focus is on measurable dermatologic outcomes relevant to patient care.
- HiSCR50
- Treatment response
- Therapeutic efficacy
This places her work within outcome-driven dermatology, where clinical benefit is evaluated through structured disease activity measures.
Adolescent and Adult Dermatology
Her trial portfolio spans both adult and adolescent populations, indicating involvement in age-diverse dermatologic care for moderate to severe hidradenitis suppurativa. This broadens the therapeutic relevance of her work across different patient groups.
- Adolescent dermatology
- Adult patient care
- Moderate to severe disease
Her research interest is therefore positioned at the intersection of chronic inflammatory skin disease and population-specific treatment evaluation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.